Literature DB >> 11772672

Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets.

Richard J Hamilton1, Ruben E Olmedo, Sachin Shah, Oliver L Hung, Mary Ann Howland, Jeanmarie Perrone, Lewis S Nelson, Neal L Lewin, Robert S Hoffman.   

Abstract

UNLABELLED: Rapid and ultrarapid opioid detoxification (ROD and UROD) centers promise quick, painless, same-day detoxification treatment for patients with opioid addiction. The goal of ROD and UROD is to provide a rapid transition from opioid dependency to oral naltrexone therapy. The patient is given general anesthesia and high-dose opioid antagonists. This induces a severe withdrawal but spares the patient the experience. In theory, the process is complete within four to five hours. The patient awakens without opioid dependency and is started on oral naltrexone. Any subsequent, persistent withdrawal symptoms are treated symptomatically. A novel, unapproved approach is to compound a pellet of naltrexone and implant it in the subcutaneous tissue. In theory, this should result in continuous therapeutic levels for this drug, and avoid issues with noncompliance. CASE SERIES: This article reports six cases of complications from the same detoxification center that performed UROD with naltrexone pellet implantation, including pulmonary edema, prolonged withdrawal, drug toxicity, withdrawal from cross-addiction to alcohol and benzodiazepines, variceal rupture, aspiration pneumonia, and death.
CONCLUSIONS: The risks of this procedure are great and further studies should assess its safety and the novel use of naltrexone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772672     DOI: 10.1111/j.1553-2712.2002.tb01169.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  7 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

3.  Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.

Authors:  Gary K Hulse; Robert J Tait; Sandra D Comer; Maria A Sullivan; Ian G Jacobs; Diane Arnold-Reed
Journal:  Drug Alcohol Depend       Date:  2005-09-01       Impact factor: 4.492

Review 4.  The effects of opioids on the lung.

Authors:  Joshua B Radke; Kelly P Owen; Mark E Sutter; Jonathan B Ford; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

Review 5.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

6.  Comment on "Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naive methadone-intoxicated patients".

Authors:  Benjamin D Kessler; Robert S Hoffman
Journal:  Biomed Res Int       Date:  2014-03-11       Impact factor: 3.411

7.  Ultrarapid opioid detoxification: current status in iran and controversies.

Authors:  Seyyed Mojtaba Yassini Ardekani; Sara Yassini Ardekani
Journal:  Int J High Risk Behav Addict       Date:  2013-12-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.